During the pandemic, the rate of healthcare facility-onset MRSA bacteremia was five times greater in patients admitted with COVID-19. Presence of central lines and mechanical ventilation are likely contributing factors for this increased rate. The number of central line-associated bacteremias may be underestimated in patients with COVID-19.
Background The impact of COVID-19 on persons living with diagnosed HIV (PLWDH) remains incompletely understood. It’s unclear whether an impaired immune system offers protection against mounting cytokine storm. Methods Retrospective matched cohort study of COVID-19 hospitalized individuals in New York State (NYS). Medical records were abstracted and analyzed for 853 PLWDH hospitalized with COVID-19 in NYS and 1621 HIV-negative controls. Preexisting comorbidities and inflammatory markers measured within 24 h of hospital admission were abstracted. Results PLWDH were significantly less likely to have elevated inflammatory markers compared to matched controls. Elevated WBC occurred in 23.3% of PLWDH vs 30.1% of controls ( p = .0002), elevated CRP in 37.4% of PLWDH vs 43.2% of controls ( p = .03), elevated ferritin in 73.4% of PLWDH vs 78.9% of controls ( p = .004). There was an inverse but not statistically significant relationship between the frequency of elevated inflammatory markers and HIV disease stage, with greatest percent of PLWDH with elevated WBC, LDH, CRP, and ferritin among PLWDH with HIV disease stage 1. Conclusion PLWDH had lower inflammatory marker elevation during COVID-19 infection compared to matched controls. PLWDH with low CD4 were less likely to mount a cytokine storm in the setting of impaired immune function.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.